Key Points
-
RB is a central regulator of cell cycle entry, and its function is disrupted in most human cancers.
-
RB is a modular protein, with three domains, and this structure allows it to function as an adaptor that nucleates several different protein complexes.
-
RB inhibits transcription by E2F transcription factors to prevent cell cycle advancement.
-
Stabilization of p27 expression through RB inhibition of S phase kinase-associated protein 2 (SKP2) inhibits cell cycle progression. Through this mechanism, RB regulates cyclin-dependent kinase (CDK) activity independently of transcription.
-
RB is required for loading condensin II and cohesin complexes onto mitotic chromosomes. In the absence of this function, defective chromosome condensation and congression in mitosis lead to aneuploidy.
-
RB uses an alternative interaction with E2F1 to regulate apoptosis separately from E2F-dependent control of the cell cycle.
Abstract
Inactivation of the RB protein is one of the most fundamental events in cancer. Coming to a molecular understanding of its function in normal cells and how it impedes cancer development has been challenging. Historically, the ability of RB to regulate the cell cycle placed it in a central role in proliferative control, and research focused on RB regulation of the E2F family of transcription factors. Remarkably, several recent studies have found additional tumour-suppressor functions of RB, including alternative roles in the cell cycle, maintenance of genome stability and apoptosis. These advances and new structural studies are combining to define the multifunctionality of RB.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Friend, S. H. et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323, 643–646 (1986).
Classon, M. & Harlow, E. The retinoblastoma tumour suppressor in development and cancer. Nature Rev. Cancer 2, 910–917 (2002).
Sherr, C. J. & McCormick, F. The RB and p53 pathways in cancer. Cancer Cell 2, 103–112 (2002).
van den Heuvel, S. & Dyson, N. J. Conserved functions of the pRB and E2F families. Nature Rev. Mol. Cell Biol. 9, 713–724 (2008).
Burkhart, D. L. & Sage, J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nature Rev. Cancer 8, 671–682 (2008).
Manning, A. L. & Dyson, N. J. RB: mitotic implications of a tumour suppressor. Nature Rev. Cancer 12, 20–226 (2012).
MacPherson, D. & Dyer, M. A. Retinoblastoma: from the two-hit hypothesis to targeted chemotherapy. Cancer Res. 67, 7547–7550 (2007).
Knudsen, E. S. & Knudsen, K. E. Tailoring to RB: tumour suppressor status and therapeutic response. Nature Rev. Cancer 8, 714–724 (2008).
Dyson, N. The regulation of E2F by pRB-family proteins. Genes Dev. 12, 2245–2262 (1998).
Lee, J.-O., Russo, A. A. & Pavletich, N. P. Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7. Nature 391, 859–865 (1998).
Hassler, M. et al. Crystal structure of the retinoblastoma protein N domain provides insight into tumor suppression, ligand interaction, and holoprotein architecture. Mol. Cell 28, 371–385 (2007).
Rubin, S. M., Gall, A. L., Zheng, N. & Pavletich, N. P. Structure of the Rb C-terminal domain bound to E2F1–DP1: a mechanism for phosphorylation-induced E2F release. Cell 123, 1093–1106 (2005).
Burke, J. R., Deshong, A. J., Pelton, J. G. & Rubin, S. M. Phosphorylation-induced conformational changes in the retinoblastoma protein inhibit E2F transactivation domain binding. J. Biol. Chem. 285, 16286–16293 (2010).
Burke, J. R., Hura, G. L. & Rubin, S. M. Structures of inactive retinoblastoma protein reveal multiple mechanisms for cell cycle control. Genes Dev. 26, 1156–1166 (2012). Examines molecular contacts of phosphates on RB and how they influence the structure of the pocket domain.
Lee, C., Chang, J. H., Lee, H. S. & Cho, Y. Structural basis for the recognition of the E2F transactivation domain by the retinoblastoma tumor suppressor. Genes Dev. 16, 3199–3212 (2002).
Xiao, B. et al. Crystal structure of the retinoblastoma tumor suppressor protein bound to E2F and the molecular basis of its regulation. Proc. Natl Acad. Sci. USA 100, 2363–2368 (2003).
Kim, H.-Y., Ahn, B.-Y. & Cho, Y. Structural basis for the inactivation of retinoblastoma tumor suppressor by SV40 large T antigen. EMBO J. 20, 295–304 (2001).
Lee, J. O., Russo, A. A. & Pavletich, N. P. Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7. Nature 391, 859–865 (1998).
Brehm, A. & Kouzarides, T. Retinoblastoma protein meets chromatin. Trends Biochem. Sci. 24, 142–145 (1999).
Morris, E. J. & Dyson, N. J. Retinoblastoma protein partners. Adv. Cancer Res. 82, 1–54 (2001).
Singh, M., Krajewski, M., Mikolajka, A. & Holak, T. A. Molecular determinants for the complex formation between the retinoblastoma protein and LXCXE sequences. J. Biol. Chem. 280, 37868–37876 (2005).
Binne, U. K. et al. Retinoblastoma protein and anaphase-promoting complex physically interact and functionally cooperate during cell-cycle exit. Nature Cell Biol. 9, 225–232 (2007).
Longworth, M. S., Herr, A., Ji, J. Y. & Dyson, N. J. RBF1 promotes chromatin condensation through a conserved interaction with the condensin II protein dCAP-D3. Genes Dev. 22, 1011–1024 (2008).
Fera, D. et al. Identification and characterization of small molecule antagonists of pRb inactivation by viral oncoproteins. Chem. Biol. 19, 518–528 (2012).
Dick, F. A. & Dyson, N. pRB contains an E2F1-specific binding domain that allows E2F1-induced apoptosis to be regulated separately from other E2F activities. Mol. Cell 12, 639–649 (2003).
Julian, L. M., Palander, O., Seifried, L. A., Foster, J. E. & Dick, F. A. Characterization of an E2F1-specific binding domain in pRB and its implications for apoptotic regulation. Oncogene 27, 1572–1579 (2008).
Adams, P. D. et al. Retinoblastoma protein contains a C-terminal motif that targets it for phosphorylation by cyclin–CDK complexes. Mol. Cell. Biol. 19, 1068–1080 (1999).
Hirschi, A. et al. An overlapping kinase and phosphatase docking site regulates activity of the retinoblastoma protein. Nature Struct. Mol. Biol. 17, 1051–1057 (2010). Demonstrates that CDKs and phosphatases compete for access to a common binding site on RB to regulate the phosphorylation status.
Pan, W., Cox, S., Hoess, R. H. & Grafstrom, R. H. A cyclin D1/cyclin-dependent kinase 4 binding site within the C domain of the retinoblastoma protein. Cancer Res. 61, 2885–2891 (2001).
Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell 81, 323–330 (1995).
Hiebert, S. W., Chellappan, S. P., Horowitz, J. M. & Nevins, J. R. The interaction of RB with E2F coincides with an inhibition of the transcriptional activity of E2F. Genes Dev. 6, 177–185 (1992).
Qin, X. Q., Chittenden, T., Livingston, D. M. & Kaelin, W. G. Jr. Identification of a growth suppression domain within the retinoblastoma gene product. Genes Dev. 6, 953–964 (1992).
Rubin, S. M. Deciphering the retinoblastoma protein phosphorylation code. Trends Biochem. Sci. 38, 12–19 (2013).
Brown, V. D., Phillips, R. A. & Gallie, B. L. Cumulative effect of phosphorylation of pRB on regulation of E2F activity. Mol. Cell. Biol. 19, 3246–3256 (1999).
Knudsen, E. S. & Wang, J. Y. Dual mechanisms for the inhibition of E2F binding to RB by cyclin-dependent kinase-mediated RB phosphorylation. Mol. Cell. Biol. 17, 5771–5783 (1997).
Kolupaeva, V. & Janssens, V. PP1 and PP2A phosphatases - cooperating partners in modulating retinoblastoma protein activation. FEBS J. 280, 627–643 (2012).
Munro, S., Carr, S. M. & La Thangue, N. B. Diversity within the pRb pathway: is there a code of conduct? Oncogene 31, 4343–4352 (2012).
Knudsen, E. S. & Wang, J. Y. Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites. J. Biol. Chem. 271, 8313–8320 (1996).
Harbour, J., Luo, R., Dei Santi, A., Postigo, A. & Dean, D. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 98, 859–869 (1999).
Isaac, C. E. et al. The retinoblastoma protein regulates pericentric heterochromatin. Mol. Cell. Biol. 26, 3659–3671 (2006).
Talluri, S. et al. A G1 checkpoint mediated by the retinoblastoma protein that is dispensable in terminal differentiation but essential for senescence. Mol. Cell. Biol. 30, 948–960 (2010).
Chicas, A. et al. Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence. Cancer Cell 17, 376–387 (2010). Identifies precise E2F targets for RB-dependent repression in senescence by chromatin immunoprecipitation followed by sequencing and microarray approaches.
Dannenberg, J.-H., van Rossum, A., Schuijff, L. & te Riele, H. Ablation of the retinoblastoma gene family deregulates G1 control causing immortalization and increased cell turnover under growth-restricting conditions. Genes Dev. 14, 3051–3064 (2000).
Sage, J. et al. Targeted disruption of the three Rb-related genes leads to loss of G1 control and immortalization. Genes Dev. 14, 3037–3050 (2000).
Bourgo, R. J. et al. RB restricts DNA damage-initiated tumorigenesis through an LXCXE-dependent mechanism of transcriptional control. Mol. Cell 43, 663–672 (2011).
Moberg, K., Starz, M. A. & Lees, J. A. E2F-4 switches from p130 to p107 and pRB in response to cell cycle reentry. Mol. Cell. Biol. 16, 1436–1449 (1996).
Hurford, R. K. Jr, Cobrinik, D., Lee, M. H. & Dyson, N. pRB and p107/p130 are required for the regulated expression of different sets of E2F responsive genes. Genes Dev. 11, 1447–1463 (1997).
Cam, H. et al. A common set of gene regulatory networks links metabolism and growth inhibition. Mol. Cell 16, 399–411 (2004).
Litovchick, L. et al. Evolutionarily conserved multisubunit RBL2/p130 and E2F4 protein complex represses human cell cycle-dependent genes in quiescence. Mol. Cell 26, 539–551 (2007).
Korenjak, M. et al. Native E2F/RBF complexes contain Myb-interacting proteins and repress transcription of developmentally controlled E2F target genes. Cell 119, 181–193 (2004).
Litovchick, L., Florens, L. A., Swanson, S. K., Washburn, M. P. & DeCaprio, J. A. DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assembly. Genes Dev. 25, 801–813 (2011)
Pilkinton, M., Sandoval, R. & Colamonici, O. R. Mammalian Mip/LIN-9 interacts with either the p107, p130/E2F4 repressor complex or B-Myb in a cell cycle-phase-dependent context distinct from the Drosophila dREAM complex. Oncogene 26, 7535–7543 (2007).
Sadasivam, S., Duan, S. & DeCaprio, J. A. The MuvB complex sequentially recruits B-Myb and FoxM1 to promote mitotic gene expression. Genes Dev. 26, 474–489 (2012).
Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).
Chen, D. et al. Division and apoptosis of E2f-defient retinal progenitors. Nature 462, 925–929 (2009). Reveals the surprising finding that activator E2F family proteins are dispensable for proliferation in the developing retina.
Chong, J. L. et al. E2f1–3 switch from activators in progenitor cells to repressors in differentiating cells. Nature 462, 930–934 (2009). Demonstrates the paradox that activator E2Fs are only required for repression and cell cycle exit in the intestine.
Ji, P. et al. An Rb–Skp2–p27 pathway mediates acute cell cycle inhibition by Rb and is retained in a partial-penetrance Rb mutant. Mol. Cell 16, 47–58 (2004).
Gao, D. et al. Cdh1 regulates cell cycle through modulating the claspin/Chk1 and the Rb/E2F1 pathways. Mol. Biol. Cell 20, 3305–3316 (2009).
Wang, H. et al. Skp2 is required for survival of aberrantly proliferating Rb1-deficient cells and for tumorigenesis in Rb1+/− mice. Nature Genet. 42, 83–88 (2010). Determines that SKP2 deficiency stabilizes p27 expression and prevents tumorigenesis in Rb+/− mice.
Schvartzman, J. M., Duijf, P. H., Sotillo, R., Coker, C. & Benezra, R. Mad2 is a critical mediator of the chromosome instability observed upon Rb and p53 pathway inhibition. Cancer Cell 19, 701–714 (2011).
Kabeche, L. & Compton, D. A. Checkpoint-independent stabilization of kinetochore–microtubule attachments by Mad2 in human cells. Curr. Biol. 22, 638–644 (2012).
Bester, A. C. et al. Nucleotide deficiency promotes genomic instability in early stages of cancer development. Cell 145, 435–446 (2011). Demonstrates that loss of RB function leads to nucleotide deficiency and aberrant DNA replication.
Gonzalo, S. et al. Role of the RB1 family in stabilizing histone methylation at constitutive heterochromatin. Nature Cell Biol. 7, 420–428 (2005).
Benetti, R. et al. Suv4-20h deficiency results in telomere elongation and derepression of telomere recombination. J. Cell Biol. 178, 925–936 (2007).
Manning, A. L., Longworth, M. S. & Dyson, N. J. Loss of pRB causes centromere dysfunction and chromosomal instability. Genes Dev. 24, 1364–1376 (2010). Shows that RB controls centromere structure and function and that in its absence mitotic errors lead to aneuploidy.
Coschi, C. H. et al. Mitotic chromosome condensation mediated by the retinoblastoma protein is tumor-suppressive. Genes Dev. 24, 1351–1363 (2010). Demonstrates, using a knock-in mutant of RB, that defective chromosome condensation contributes to cancer pathogenesis.
van Harn, T. et al. Loss of Rb proteins causes genomic instability in the absence of mitogenic signaling. Genes Dev. 24, 1377–1388 (2010). Shows that deletion of all three RB-family proteins causes chromosomal breaks and aneuploidy.
Zhang, J. et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 481, 329–334 (2012).
Trimarchi, J. M. & Lees, J. A. Sibling rivalry in the E2F family. Nature Rev. Mol. Cell Biol. 3, 11–20 (2002).
Wu, L. et al. Extra-embryonic function of Rb is essential for embryonic development and viability. Nature 421, 942–947 (2003).
Ianari, A. et al. Proapoptotic function of the retinoblastoma tumor suppressor protein. Cancer Cell 15, 184–194 (2009). Reveals that phosphorylated RB participates in a transcriptional activation mechanism that drives the expression of apoptotic target genes in response to DNA damage.
Helin, K. et al. A cDNA encoding a pRB-binding protein with properties of the transcription factor E2F. Cell 70, 337–350 (1992).
Seifried, L. A. et al. pRB–E2F1 complexes are resistant to adenovirus E1A-mediated disruption. J. Virol. 82, 4511–4520 (2008).
Cecchini, M. J. & Dick, F. A. The biochemical basis of CDK phosphorylation-independent regulation of E2F1 by the retinoblastoma protein. Biochem. J. 434, 297–308 (2011).
Wells, J., Yan, P. S., Cechvala, M., Huang, T. & Farnham, P. J. Identification of novel pRb binding sites using CpG microarrays suggests that E2F recruits pRb to specific genomic sites during S phase. Oncogene 22, 1445–1460 (2003).
Avni, D. et al. Active localization of the retinoblastoma protein in chromatin and its response to S phase DNA damage. Mol. Cell 12, 735–746 (2003).
Calbo, J. et al. G1 cyclin/cyclin-dependent kinase-coordinated phosphorylation of endogenous pocket proteins differentially regulates their interactions with E2F4 and E2F1 and gene expression. J. Biol. Chem. 277, 50263–50274 (2002).
Carnevale, J., Palander, O., Seifried, L. A. & Dick, F. A. DNA damage signals through differentially modified E2F1 molecules to induce apoptosis. Mol. Cell. Biol. 32, 900–912 (2012).
Bosco, E. E. et al. The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. J. Clin. Invest. 117, 218–228 (2007).
Hallstrom, T. C., Mori, S. & Nevins, J. R. An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. Cancer Cell 13, 11–22 (2008).
Irwin, M. S. et al. Chemosensitivity linked to p73 function. Cancer Cell 3, 403–410 (2003).
Carr, S. M., Munro, S., Kessler, B., Oppermann, U. & La Thangue, N. B. Interplay between lysine methylation and Cdk phosphorylation in growth control by the retinoblastoma protein. EMBO J. 30, 317–327 (2011).
Chan, H. M., Krstic-Demonacos, M., Smith, L., Demonacos, C. & La Thangue, N. B. Acetylation control of the retinoblastoma tumour-suppressor protein. Nature Genet. 3, 667–674 (2001).
Markham, D., Munro, S., Soloway, J., O'Connor, D. P. & La Thangue, N. B. DNA-damage-responsive acetylation of pRb regulates binding to E2F-1. EMBO Rep. 7, 192–198 (2006).
Munro, S., Khaire, N., Inche, A., Carr, S. & La Thangue, N. B. Lysine methylation regulates the pRb tumour suppressor protein. Oncogene 29, 2357–2367 (2010).
Saddic, L. A. et al. Methylation of the retinoblastoma tumor suppressor by SMYD2. J. Biol. Chem. 285, 37733–37740 (2010).
Henley, S. A. & Dick, F. A. The retinoblastoma family of proteins and their regulatory functions in the mammalian cell division cycle. Cell Div. 7, 10 (2012).
Cobrinik, D. Pocket proteins and cell cycle control. Oncogene 24, 2796–2809 (2005).
Jacks, T. et al. Effects of an Rb mutation in the mouse. Nature 359, 295–300 (1992).
Lee, M. H. et al. Targeted disruption of p107: functional overlap between p107 and Rb. Genes Dev. 10, 1621–1632 (1996).
Cobrinik, D. et al. Shared role of the pRB-related p130 and p107 proteins in limb development. Genes Dev. 10, 1633–1644 (1996).
Lamber, E.P. et al. Structural insights into the mechanism of phosphoregulation of the retinoblastoma protein. PLoS ONE 8, e58463 (2013).
Acknowledgements
Research in the authors laboratories is supported by awards from the Canadian Institutes of Health Research (MOP89765 and MOP64253) and the Canadian Cancer Society Research Institute (2011-700720) to F.A.D, and the US National Institutes of Health (R01CA132685) and the American Cancer Society (RSG-12-131-01-CCG) to S.M.R. F.A.D is The Wolfe Senior Fellow in Tumour Suppressor Genes.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Related links
Related links
DATABASES
Protein Data Bank
FURTHER INFORMATION
Glossary
- Cyclin
-
A family of proteins that activate cyclin-dependent kinases and whose stability is cell-cycle regulated.
- CDK
-
(Cyclin-dependent kinase). A family of kinases that are activated by cyclins.
- E2F
-
(E2-binding factor). A family of cell-cycle regulated transcription factors.
-
A region in RB-family proteins that was originally determined to bind to viral oncoproteins, such as SV40 TAg.
- Differentiation-related polypeptide
-
(DP). The E2F dimerization partner.
- Pocket proteins
-
RB-family proteins, defined by their possession of the central 'pocket' domain.
- p27
-
An inhibitor of cyclin-dependent kinase activity.
- F box protein
-
A protein containing the F box domain, an approximately 50-amino acid motif that facilitates protein–protein interactions.
- S phase kinase-associated protein 2
-
(SKP2). An adaptor protein that recruits p27 to the SKP–cullin–F box E3 ligase complex.
- APC/C
-
(Anaphase-promoting complex; also known as the cyclosome). An E3 ubiquitin ligase.
- Merotelic
-
When multiple microtubules, emanating from opposite spindle poles, simultaneously bind to a single kinetochore.
- Aneuploidy
-
An abnormal number of chromosomes in a cell.
- Centromere
-
A constricted region of a chromosome that interacts with kinetochores and is the attachment point for spindle microtubules.
- Condensin II
-
A protein complex made up of seven protein subunits that create a ring structure to link and supercoil DNA strands.
- Cohesin
-
A ring-structured protein complex similar to the condensins that creates cohesion between replicated, homologous DNA strands and regulates their separation during cell division.
- Pericentromere
-
A repetitive chromosomal region adjacent to the centromere.
Rights and permissions
About this article
Cite this article
Dick, F., Rubin, S. Molecular mechanisms underlying RB protein function. Nat Rev Mol Cell Biol 14, 297–306 (2013). https://doi.org/10.1038/nrm3567
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrm3567
This article is cited by
-
Profound DNA methylomic differences between single- and multi-fraction alpha irradiations of lung fibroblasts
Clinical Epigenetics (2023)
-
Genetics in ophthalmology: molecular blueprints of retinoblastoma
Human Genomics (2023)
-
CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy
Nature Communications (2023)
-
CHRM4/AKT/MYCN upregulates interferon alpha-17 in the tumor microenvironment to promote neuroendocrine differentiation of prostate cancer
Cell Death & Disease (2023)
-
Selective activator of human ClpP triggers cell cycle arrest to inhibit lung squamous cell carcinoma
Nature Communications (2023)